The resulting paper, "HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease," appears in the American Journal of Gastroenterology.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its ...

Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

The extension study found that anti-drug antibodies and undetectable drug levels were associated with both treatment without an accompanying immunomodulator and carriage of the HLA-DQA1*05 genetic ...

Immunogenicity Screening: The platform identifies immunogenic hotspots and predicts potential adverse immune responses, reducing the risk of anti-drug antibody formation and optimizing patient ...

Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of ...

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

The resulting paper, “HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease” appeared in the American Journal of Gastroenterology.